The Impact of Protein Supplementation Targeted at Improving Muscle Mass on Strength in Cancer Patients: A Scoping Review
Open Access
Abstract
Deterioration of muscle strength during cancer results in functional limitation, poor quality of life and reduced survival. The indirect effects on muscle strength of nutritional interventions based on protein and amino acid derivatives targeted at improving muscle mass are poorly documented. A scoping review was performed to examine the available evidence on the effects of proteins, amino acids and their derivatives on muscle strength in adult cancer patients. Pubmed and Scopus databases were searched to identify research articles published in the last 10 years. Fourteen studies met the inclusion criteria, showing that changes in muscle strength following protein or amino acid supplementation are generally concordant with those in muscle mass in cancer patients. Administration of both energy and proteins in the presence of reduced oral intakes results in more robust effects on both muscle strength and mass. It is not clear whether this is due to the correction of the energy deficit or to an interaction between proteins and other macronutrients. The optimal mixture, type, and dose of amino acid/protein supplementation alone or in combination with other anabolic strategies should be determined to provide the best nutritional approach in cancer.Keywords
This publication has 61 references indexed in Scilit:
- Sarcopenia Predicts Early Dose-Limiting Toxicities and Pharmacokinetics of Sorafenib in Patients with Hepatocellular CarcinomaPLOS ONE, 2012
- Hand-grip strength is a simple and effective outcome predictor in esophageal cancer following esophagectomy with reconstruction: a prospective studyJournal of Cardiothoracic Surgery, 2011
- Definition and classification of cancer cachexia: an international consensusThe Lancet Oncology, 2011
- Cancer‐related fatigue: the impact of skeletal muscle mass and strength in patients with advanced cancerJournal of Cachexia, Sarcopenia and Muscle, 2010
- Determinants of hand grip strength, knee extension strength and functional status in cancer patientsClinical Nutrition, 2010
- Randomized Phase III Clinical Trial of Five Different Arms of Treatment in 332 Patients with Cancer CachexiaThe Oncologist, 2010
- Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinomaAnnals of Oncology, 2010
- Sarcopenia as a Determinant of Chemotherapy Toxicity and Time to Tumor Progression in Metastatic Breast Cancer Patients Receiving Capecitabine TreatmentClinical Cancer Research, 2009
- Body Composition as an Independent Determinant of 5-Fluorouracil–Based Chemotherapy ToxicityClinical Cancer Research, 2007
- Scoping studies: towards a methodological frameworkInternational Journal of Social Research Methodology, 2005